Otsuka Pharmaceutical has completed its acquisition of Transcend Therapeutics, with New York-based Transcend now a wholly owned subsidiary of Otsuka America, Inc., the US arm of Japan-based Otsuka Pharmaceutical Co., Ltd. The deal, originally announced in March 2026, positions Otsuka to advance TSND-201 (methylone), a Phase III-stage neuroplastogen for post-traumatic stress disorder, through a therapeutic area where no new FDA-approved treatments have emerged in over two decades.
The transaction was structured as a full corporate acquisition, with Otsuka America paying USD 700 million upfront and Transcend shareholders eligible for up to USD 525 million in contingent commercial sales milestone payments, bringing total potential consideration to USD 1.225 billion. No individual milestone tiers were disclosed. Because the deal is a whole-company acquisition rather than a territorial license, Otsuka obtains worldwide, unrestricted rights to Transcend's entire portfolio across all indications. Closing conditions have now been satisfied.
TSND-201 is classified as a rapid-acting neuroplastogen — an agent designed to induce rapid and durable neural plasticity through action on monoamine transporters for serotonin, norepinephrine, and dopamine. Critically, the compound has no activity at the serotonin 5-HT2A receptor, which mediates hallucinogenic effects, distinguishing it from classical psychedelics such as psilocybin and from MDMA-based approaches currently in development. This non-hallucinogenic profile is clinically significant: it may eliminate the need for the extended supervised psychotherapy sessions that characterize psychedelic-assisted therapy models, simplifying administration and potentially broadening patient access.
In the Phase II IMPACT-1 trial — a randomized, double-blind, placebo-controlled study enrolling 65 adults with severe PTSD across 16 sites — TSND-201 demonstrated a statistically significant placebo-adjusted improvement in CAPS-5 total severity scores of −9.64 points at Day 64 (p = 0.011), with statistically significant separation from placebo observed as early as Day 10. Results were published in JAMA Psychiatry. The US FDA granted TSND-201 Breakthrough Therapy Designation in July 2025, and the program subsequently received an FDA Commissioner's National Priority Voucher. A Phase III trial for PTSD is currently ongoing.